Moderna Reports Results of Bivalent Booster mRNA -1273.214 in P-II/III Trial Demonstrated Superior Antibody Response Against Omicron
- The P-II/III trial evaluate mRNA-1273.214 (50µg) vs mRNA-1273 (50µg) booster dose in 437 patients against Omicron
- The trial met all 1EPs including neutralizing Ab response over 50µg booster dose of mRNA-1273 in baseline seronegative patients, superiority is determined by neutralizing GMR with the lower bound of the confidence interval >1 using pre-specified criteria, mRNA-1273.214 exhibited an 8-fold increased in neutralizing GMT against omicron, MSD was higher against all other VOC, safety & tolerability was consistent with a prior booster dose of mRNA-1273
- Additionally, non-inferiority was also met against SARS-CoV-2 with GMR. The company intends to submit an interim study & data to regulators for review in the coming wks.
Ref: Moderna | Image: Moderna
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.